KLOW Online

a reading room for the four-peptide record

KLOW peptide is a four-part research blend, and the blend itself has never been tested.

Four peptides in one vial: KPV, GHK-Cu, BPC-157, TB-500. Four separate marks. Each one studied alone. The combination, never. We read them one at a time.

Read the recordKLOW vs GLOW
Hand-drawn composition of four distinct cool-ink specimen marks — sage, stone, slate-blue and dusty-teal — for the four KLOW peptides, with one element left as an empty sketched outline marking the missing combination data

The short version

KLOW peptide is a research-only blend of four peptides mixed into one vial. The four are KPV, GHK-Cu, BPC-157 and TB-500. They stay four separate molecules — KLOW is not one new drug, it is four things dissolved together.

Each one was studied on its own, mostly in cells and rats. KPV calms inflammation. GHK-Cu (a copper-carrying peptide) helps skin make collagen. BPC-157 helps gut and tendon tissue heal in animals. TB-500 helps wounds close. Put together, the idea is that they cover four steps of repair at once.

But here is the honest part: no study has ever tested the four-peptide KLOW blend itself. Every "they work better together" claim is a guess built from the single-peptide research, not proof. KLOW is not a weight-loss drug, and it is not FDA-approved. What people report — the upsides and the downsides — is on benefits and reported effects.

What is KLOW peptide?

KLOW is a research-only co-formulation of four distinct peptides: KPV, GHK-Cu, BPC-157 and TB-500. They are co-dissolved in one vial at fixed mass ratios. They do not fuse into a single chemical entity — four molecules share the vial, nothing more [1].

The most widely listed research-vial composition is an 80 mg total: GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg, KPV 10 mg. There is no FDA-approved or pharmacopeial KLOW product. It is supplied strictly as a research-chemical co-formulation.

KLOW carries no single CAS number, no single molecular weight, no single PubChem entry. A mixture has no identity of its own. Each constituent has its own identifiers; the blend has none.

KLOW as a four-peptide co-formulation

Four peptides. Four jobs. One cascade of tissue repair.

  • KPV — the anti-inflammatory arm. A tripeptide, Lys-Pro-Val, the tail end of alpha-MSH (a hormone that, among other things, dials down inflammation). It suppresses NF-kB (a master switch for inflammatory genes) and lowers inflammatory signals in cells [2].
  • GHK-Cu — the matrix arm, and the mass-dominant one. About 62.5% of the canonical vial. A copper-carrying tripeptide that pushes cells to build collagen and that shifts a large slice of the genes a skin cell uses [7][8].
  • BPC-157 — the blood-vessel and connective-tissue arm. A 15-amino-acid peptide that, in rats, speeds tendon and gut healing and grows new vessels [5][4].
  • TB-500 — the cytoskeleton arm. A short fragment of thymosin beta-4 that binds actin, a step tied to cells crawling into a wound [6].

The rationale for combining them is mechanistic: four non-overlapping nodes of one repair network. Mechanistic is the right word — and the limit. No study tested the four-peptide blend together [1].

What is in the 80 mg KLOW vial?

The most widely listed composition: GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg + KPV 10 mg = 80 mg total.

GHK-Cu is mass-dominant — roughly 62.5% of the vial. The other three split the rest evenly. The four are co-dissolved at fixed ratios but remain separate molecules; the vial is a mixture, not a compound [1].

A note that follows from the chemistry, not from any blend study: the four peptides clear the body at very different speeds. BPC-157 has a very short elimination half-life — under about 30 minutes in the formal study — and the two tripeptides clear even faster [9]. One co-dissolved dose cannot hold all four at matched levels. The full picture is on the doses used in the component research.

What does the KLOW peptide do?

Its four arms occupy non-overlapping nodes of one tissue-repair network. KPV suppresses inflammatory transcription [2]. GHK-Cu drives collagen and matrix synthesis and supplies copper for the enzymes that crosslink collagen [7]. BPC-157 promotes angiogenesis (the growth of new blood vessels) and connective-tissue repair in animals [5][3]. TB-500, through the actin-binding motif of thymosin beta-4, aids cell migration and wound closure [6].

That combined action is a rationale, not a result. No controlled study has tested the four together [1]. For what the published single-component literature actually measured, read the published study findings.